GSK Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
This GSK Company BD Opportunity Scan Report was built with PatSnap Life Sciences MCP workflows. Company & Deal Intelligence MCP connects the organization pipeline, transaction precedents and financial-report signals; Current Awareness MCP tests for recent-event context. The output is a partnering shortlist with owner, stage, evidence package, IP risk, deal precedent and outreach rationale. Explore the MCP servers used in this report.
Decision date: 22 July 2026. This is a screening memorandum for business-development prioritization, not legal, patent, medical or investment advice. “Not returned” means the searched MCP result did not supply a usable record and must not be read as evidence of absence.
Executive BD thesis
GSK is screened as a potential partnering counterparty across asset licensing, regional commercialization, co-development, platform access and evidence-generation structures. The organization pipeline call returned 1900 records at the decision date. The lead returned asset is Linerixibat, associated with ISBT and Primary Biliary Cholangitis, Cholestatic pruritus, Diabetes Mellitus, Type 2, Cholestasis, at Approved. The immediate objective is to identify a narrow, executable right set and the evidence package required to test strategic fit.
A high-quality first meeting should confirm the current development owner, decision rights, territory availability, stage definitions, program status, patent ownership, third-party licenses, CMC readiness, clinical evidence, regulatory history and management’s preferred transaction structure. Pipeline size is a starting signal, not a substitute for strategic fit or diligence.
Partnering shortlist
| Priority | Asset / workstream | Owner | Stage | Evidence package | IP risk screen | Deal precedent | Outreach rationale |
|---|---|---|---|---|---|---|---|
| 1 | Linerixibat | GlaxoSmithKline UK Ltd. | Approved | Pipeline record: ISBT; Primary Biliary Cholangitis, Cholestatic pruritus, Diabetes Mellitus, Type 2, Cholestasis. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs | Approved asset with ISBT exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 2 | Depemokimab | GlaxoSmithKline Trading Services Ltd. | Approved | Pipeline record: IL-5; Eosinophilic Asthma, Severe asthma, Asthma, Chronic rhinosinusitis with nasal polyps. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | GSK completes acquisition of Nuvalent, Inc. | Approved asset with IL-5 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 3 | Gepotidacin | GlaxoSmithKline LLC | Approved | Pipeline record: Bacterial Top II x Bacterial top IV; Bacterial urinary infection, Gonorrhea, Bacterial Infections, Urinary Tract Infections. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch | Approved asset with Bacterial Top II x Bacterial top IV exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 4 | MenABCWY vaccine (GSK) | GlaxoSmithKline Biologicals (Shanghai) Ltd. | Approved | Pipeline record: target not returned; Meningococcal Infections, Meningitis, Meningococcal. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs | Approved asset with target not returned exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
| 5 | Momelotinib Dihydrochloride | GlaxoSmithKline LLC | Approved | Pipeline record: ALK2 x JAK1 x JAK2; Post-essential thrombocythemia myelofibrosis, Post-polycythemia vera myelofibrosis, Primary Myelofibrosis, Anemia. Request current protocol history, CMC status, regulatory correspondence, safety narrative and data-room index. | Medium screening risk. Verify composition-of-matter, method-of-use, formulation or delivery claims, territory coverage, third-party licenses and freedom to operate. | GSK completes acquisition of Nuvalent, Inc. | Approved asset with ALK2 x JAK1 x JAK2 exposure; test regional rights, co-development, option-to-license, evidence generation or financing-linked structures. |
Shortlist interpretation. Priority one should receive the fastest outreach only after the returned owner and stage are reconfirmed. Lower-ranked rows preserve option value and may support a regional license, co-development collaboration, asset carve-out, structured option, research partnership or financing-linked agreement. Any mismatch among asset name, owner, indication and stage is itself a diligence signal that may reflect a transfer, dormant program, territory split or portfolio reprioritization.
Pipeline and evidence-package readout
The organization pipeline fetch anchors asset identity, target, indication and development stage when those fields are returned. Reconcile them against the sponsor’s current presentation, trial registry, regulatory correspondence and data-room index. For each shortlisted asset, request protocol history, enrollment and discontinuation data, endpoint definitions, biomarker strategy, subgroup results, safety narratives, manufacturing comparability, stability data, health-authority feedback and the sponsor’s integrated development plan.
Evidence quality is strongest when asset identity, stage, owner and indication are mutually consistent across the company record, trial registries and regulatory sources. A stage label should be translated into a milestone map with dates, endpoints, decision gates and remaining cost. Where the MCP result is missing or ambiguous, do not fill the gap by assumption: make the refresh and reconciliation an explicit condition before valuation.
Deal precedents and structure signals
| Date | Transaction | Status | Disclosed economics |
|---|---|---|---|
| 2026-07-08 | Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs | Active | Not disclosed |
| 2026-06-09 | GSK completes acquisition of Nuvalent, Inc. | Completed | Not disclosed |
| 2026-05-11 | GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch | Active | Not disclosed |
Transaction precedents guide structure rather than mechanically determine price. Normalize every comparison for stage, territory, modality, included indications, opt-in rights, cost sharing, manufacturing obligations, royalties, milestones, sublicensing, governance, termination and change-of-control provisions. Undisclosed economics can still reveal counterparties, strategic intent and preferred transaction form. A missing search result should trigger a broader licensor/licensee and asset-level search before negotiation.
Financial capacity and partnering pressure
- VG Acquisition Corp. - Prospectus(U.S. Stocks): VG Acquisition Corp. - Prospectus(U.S. Stocks) Code of Business Conduct and Ethics In July 2018, we entered into the GSK Agreement, and GSK made a $300 million investment in us on the same date. The GSK Agreement provides for an initial four-year exclusive collaboration for drug target discovery, development, and commercialization (the “Discovery Term”). GSK agreed to pay us $25 million per year for the initial four years of the Discovery Term, and has the right to extend the Discovery Term for a fifth year upon payment of an additional $50 million. To date, GSK has paid us $75 million, and the final $25 million for the fourth year of the Discovery Term is payable in July 2021. The GSK Agreement has enabled us to expand our research, discovery, development and ultimate commercialization efforts. Our collaboration with GSK combines the resources of our two companies to accelerate the iden
- Wave Life Sciences Ltd. - 2025 Quarterly report: Wave Life Sciences Ltd. - 2025 Quarterly report GSK Collaboration and Equity Agreements Under the GSK Collaboration Agreement, GSK can advance up to eight programs leveraging the Company’s PRISM platform and multiple RNA-targeting modalities (RNA editing, splicing, siRNA, and antisense) with target validation work ongoing across multiple therapy areas. GSK selected its first two programs to advance to development candidates following achievement of target validation in the three months ended June 30, 2024. These programs utilize the Company’s next generation GalNAc-siRNA format and are in hepatology. Under the GSK Collaboration Agreement, GSK was required to provide an aggregate initiation payment of $12.0 million to the Company for these two oligonucleotide programs, which was received during the three months ended June 30, 2024.fi The following table summarizes the allocation of the to
- AGENUS INC - 2023 Quarterly report: AGENUS INC - 2023 Quarterly report Gilead Collaboration Agreement Historical Results of Operations Three months ended September 30, 2023 compared to the three months ended September 30, 2022 Research and development revenue We recognized research and development revenue of approximately $3.4 million and $4.6 million during the three months ended September 30, 2023 and 2022, respectively. Research and development revenues in the third quarter of 2023 primarily consisted of $2.9 million related to the recognition of deferred revenue earned under our Gilead Collaboration Agreements. Research and development revenues in the third quarter of 2022 primarily consisted of $4.5 million related to the recognition of deferred revenue earned under our Gilead Collaboration Agreements. Non-cash royalty revenue related to the sale of future royalties In January 2018, we sold 100% of our worldwide right
Translate financial signals into BD questions. Confirm unrestricted cash, quarterly operating use, committed trials, debt and royalty financing, covenant constraints, near-term milestone receipts, commercial investment and management’s minimum runway threshold. A well-capitalized company may prefer a premium strategic collaboration; a constrained company may prioritize non-dilutive funding, regional monetization, cost sharing or a staged option.
Current-awareness events and outreach triggers
The Current Awareness news_search call did not return a parseable recent-event record at the decision date. Refresh the search before outreach and reconcile press releases, trial updates, regulatory events, financing announcements, management changes and partnering disclosures. Do not interpret the missing return as absence of news.
The best outreach window often follows a data readout, regulatory interaction, financing, portfolio review, leadership change or new transaction. Build a trigger calendar and identify the person who owns the asset, the therapeutic-area BD lead, the regional commercial lead and alliance-management stakeholders. Outreach should cite one verified event and one specific contribution the prospective partner can make.
IP and freedom-to-operate risk screen
The IP review is a gating workstream, not a footnote. Request the full patent-family schedule, inventorship and assignment history, prosecution status, expected expiries, patent-term adjustment or extension assumptions, opposition and litigation history, third-party licenses, field and territory restrictions, royalties, reach-through clauses, government rights and material-transfer obligations. Map composition-of-matter, method-of-use, formulation, manufacturing, biomarker, combination, platform and delivery claims to the exact rights proposed in the deal.
Screen risk as medium by default when an asset and owner are returned but the patent package has not been reviewed; elevate it to high where ownership, stage or program status is not returned. A license must match patents, know-how, data, regulatory references, materials, manufacturing rights and sublicensing rights to the precise field and geography. Complete a claim-level patent and FTO review before exclusivity, valuation or term-sheet approval.
Recommended deal structures
- Regional license: useful when development or commercial capabilities differ by territory; define data access, regulatory responsibilities, supply, transfer pricing and reversion rights.
- Co-development: appropriate when both parties contribute clinical, biomarker, regulatory or commercial capabilities; specify cost sharing, governance, global strategy and opt-out economics.
- Option-to-license: reduces uncertainty before a defined data event; specify option fee, exercise trigger, diligence standard, exclusivity period and pre-agreed economics.
- Research or platform collaboration: suitable when the value resides in discovery or delivery capability; define targets, ownership of foreground IP, publication, replacement rights and downstream options.
- Structured financing: may combine equity, milestone funding, royalties or territory monetization; test covenant, accounting, control and change-of-control implications.
Outreach rationale and first-contact plan
- Identify the decision owner. Map the asset team, corporate-development lead, therapeutic-area leadership, regional commercial lead and alliance-management stakeholders.
- Lead with one verifiable gap. Focus on territory, evidence, diagnostics, manufacturing, delivery, financing or combination strategy rather than a generic partnership request.
- Attach a concise evidence package. Include the returned stage, indication footprint, relevant transaction precedent, partner contribution, proposed work plan and decision gates.
- Offer a structure. Present one primary and one fallback structure with clear rights, funding, governance and diligence assumptions.
- Define the diligence sequence. Request data-room access, IP/FTO materials, CMC documents, safety data, regulatory correspondence, economics and encumbrances before exclusivity.
Decision memo
ADVANCE TARGETED OUTREACH, SUBJECT TO EVIDENCE REFRESH. GSK offers a credible screening case because the MCP workflow identifies either a returned pipeline opportunity or a concrete set of evidence gaps that can be tested rapidly. The first contact should be tailored to a named asset where available, quantify the partner’s contribution, acknowledge IP and execution risks and avoid using pipeline count as a proxy for value.
Required next diligence: refresh all four MCP searches; fetch full deal records for economics and rights; reconcile the newest financial filing and public event disclosures; verify owner and license chain; obtain patent-family and FTO work; review CMC, safety and regulatory materials; and model risk-adjusted economics by indication, territory and transaction structure.
Explore PatSnap Open Platform MCP Servers and build your next biopharma BD workflow.
Data provenance: PatSnap Company & Deal Intelligence MCP (organization_pipeline_fetch, drug_deal_search, financial_report_search) and Current Awareness MCP (news_search); accessed 22 July 2026. Counts, ownership and statuses may change as records update.
